Somer DelSignore

Call Directions Website Contact the practice

Somer DelSignore Restoring the Pediatric Terrain.” I also offer wellness consultations and IV therapy to help patients decrease inflammation and boost the immune system.

Hudson Valley Integrative Health
Dr. Somer DelSignore, DNP, Fellow MAPS, AAOT, ILADS Member Professional speaker, author and adjunct professor, CEO/Founder
“Beyond Symptoms.Beyond Diagnosis. I treat the PANS, Lyme, Autoimmune Encephalopathy and Autism connection with root cause medicine providing comprehensive, integrative consultation for pediatric patients up to 26 years old afflicted chronic underlying infection, toxic exposures and immune imbalances.

11/04/2026

Stories like Devon’s are a powerful reminder of why I do this work. 💚

Behind every complex case is a child, a family, and a parent searching for answers and hope. I’m incredibly grateful for the trust Devon and her family have placed in me over the past two years. Caring for these children means looking at the whole child, continually asking questions, investigating root causes, and adjusting our approach when needed. It is never a journey without challenges, but families should never have to navigate it alone.

🙏Thank you, Devon, for sharing your family’s story and for allowing us to be part of your daughter’s journey.

11/02/2026

When a child experiences sudden changes in behavior, including rage, OCD, anxiety, or brain fog, it's important to look at the full picture.

💡Bartonella and other infections may contribute to both physical and neurological symptoms. Don't overlook the possibility of an underlying infection when trying to understand what has changed.

🌳The goal is to ask the right questions and get to the root cause.

Halloween in Manhattan.🎃Hoping all had a safe and healthy Halloween night!
11/01/2026

Halloween in Manhattan.🎃Hoping all had a safe and healthy Halloween night!

10/30/2026

Let's talk about navigating the holiday season with a child who has a complex chronic illness. ❤️

The holidays should be about making memories, not stressing over every bite! My advice is to keep routines as consistent as possible, make cleaner swaps when you can, and allow your kids to enjoy a few of their favorite holiday treats. 🎃🎄🦃🕎

It’s all about finding balance, helping minimize potential flares, and giving yourself a little grace along the way. Remember, perfection isn’t the goal!

10/29/2026

🚨 Autism Research Update: L1-79 is heading toward Phase-3!

If you’ve seen headlines about L1-79, an experimental autism medication, here’s what the research has shown, and what’s next 👇

In 2018, L1-79 received FDA Fast Track Designation for its development as a potential treatment for some of the core symptoms of autism. Now, Yamo Pharmaceuticals is planning to begin Phase 3 clinical trials in early 2027.

What is L1-79?

L1-79 is an investigational medication that inhibits tyrosine hydroxylase, an enzyme involved in producing dopamine and norepinephrine. Researchers are investigating whether this approach may improve social-interaction symptoms associated with autism.

What have we learned so far?

In 2024, in a Phase 2 study of 58 adolescents and young adults with autism, Yamo reported statistically significant improvements compared with placebo on the Vineland-3 Socialization score.

Additionally, a 2019 case series involving eight participants reported improvements on several behavioral and clinical assessments. However, the authors emphasized that controlled studies were needed to confirm these preliminary findings.

What’s next?

Yamo Pharmaceuticals plans to advance L1-79 into Phase 3 trials in early 2027 – an important next step in evaluating its safety and effectiveness.

Important: IL1-79 is investigational and is NOT FDA-approved. Earlier results are promising but do not establish that the medication is effective, which is exactly why these phase 3 trials will be so important for further evaluating its potential benefits and risks.

💙 Follow for more evidence-based updates on autism research and emerging clinical trials.

📚 Sources:
• Rothman et al., Clinical Therapeutics, 2019 – Eight-participant case series.
• Yamo Pharmaceuticals, July 2024 – Phase 2 results announcement.
• ClinicalTrials.gov: NCT05067582 – Phase 2 study details.
• Yamo Pharmaceuticals, October 2026 – Planned Phase 3 trial updates.

For study updates and family registration information, visit access.yamopharma.com.

10/29/2026

🚨 Autism Research Update: L1-79 is heading toward Phase-3!

If you’ve seen headlines about L1-79, an experimental autism medication, here’s what the research has shown, and what’s next 👇

In 2018, L1-79 received FDA Fast Track Designation for its development as a potential treatment for some of the core symptoms of autism. Now, Yamo Pharmaceuticals is planning to begin Phase 3 clinical trials in early 2027.

What is L1-79?

L1-79 is an investigational medication that inhibits tyrosine hydroxylase, an enzyme involved in producing dopamine and norepinephrine. Researchers are investigating whether this approach may improve social-interaction symptoms associated with autism.

What have we learned so far?

In 2024, in a Phase 2 study of 58 adolescents and young adults with autism, Yamo reported statistically significant improvements compared with placebo on the Vineland-3 Socialization score.

Additionally, a 2019 case series involving eight participants reported improvements on several behavioral and clinical assessments. However, the authors emphasized that controlled studies were needed to confirm these preliminary findings.

What’s next?

Yamo Pharmaceuticals plans to advance L1-79 into Phase 3 trials in early 2027 – an important next step in evaluating its safety and effectiveness.

Important: IL1-79 is investigational and is NOT FDA-approved. Earlier results are promising but do not establish that the medication is effective, which is exactly why these phase 3 trials will be so important for further evaluating its potential benefits and risks.

💙 Follow for more evidence-based updates on autism research and emerging clinical trials.

📚 Sources:
• Rothman et al., Clinical Therapeutics, 2019 – Eight-participant case series.
• Yamo Pharmaceuticals, July 2024 – Phase 2 results announcement.
• ClinicalTrials.gov: NCT05067582 – Phase 2 study details.
• Yamo Pharmaceuticals, October 2026 – Planned Phase 3 trial updates.

For study updates and family registration information, visit access.yamopharma.com.

10/28/2026

🔎When a child’s behavior and mental health symptoms change suddenly, I believe it’s important to pause and look beyond a psychiatric diagnosis alone.

OCD, intrusive thoughts, rumination, and dramatic behavioral changes can sometimes occur alongside infections or neuroinflammation.

🌳In my practice, I commonly see strep, coxsackie, and tick-borne infections in children experiencing these kinds of symptoms.

A sudden change in your child deserves to be investigated, not dismissed.

Feeling incredibly grateful to be part of this year’s ILADS Annual Scientific Conference.💚 It’s inspiring to connect wit...
10/26/2026

Feeling incredibly grateful to be part of this year’s ILADS Annual Scientific Conference.

💚 It’s inspiring to connect with so many brilliant practitioners and thought leaders who are pushing the field forward. The growth, collaboration, and momentum within the Lyme and vector-borne disease community are exciting to witness. 

💡Most importantly, this progress brings real hope for the future of children living with complex neuroimmune conditions. The conversations we’re having and the work we’re doing today can change the trajectory of their tomorrow. So proud to be part of this community!

10/23/2026

Sometimes the most powerful stories are the ones told by the children and families who have lived them. 💚

This precious patient recently shared what life was like before seeing me for PANS and how, with a comprehensive treatment plan, she was able to get back to school, join drama club and swim team, and even earn straight A’s!

Every child’s story is different, but their experiences deserve to be heard, understood, and taken seriously.

I’m so grateful to Brynn for sharing her story. 🫶

🔎When your child’s symptoms don’t fit neatly into one diagnosis, it may be time to look at the bigger picture.Bartonella...
10/22/2026

🔎When your child’s symptoms don’t fit neatly into one diagnosis, it may be time to look at the bigger picture.

Bartonella can be challenging to recognize because symptoms may involve multiple systems and can change over time.

That doesn’t mean Bartonella is the answer to every unexplained symptom. It means it can be important to know what to look for, ask better questions, and consider the full clinical history.

If your child’s health story doesn’t quite add up, keep asking questions.

📌Save this post and share it with a parent who may need it.

Address

Telemedicine And In-person
New York, NY
10017

Opening Hours

Monday 8:30am - 4:30pm
Tuesday 8:30am - 4:30pm
Thursday 8:30am - 4:30pm
Friday 8:30am - 4:30pm

Telephone

+18455920727

Alerts

Be the first to know and let us send you an email when Somer DelSignore posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Contact The Practice

Send a message to Somer DelSignore:

Shortcuts

Sponsored

Share

Nearby clinics